Clinical Trial Results
Search
Dr. Karim Al-Azizi and Dr. C. Michael Gibson discuss: Caveat Emptor: Advantages and Disadvantages of Current Generation Tools for Evaluation of Coronary Atherosclerosis
Sponsored by Cleerly, Women as One and International Atherosclerosis Society
Dr. Nicole Cyrille Superville and Dr. C. Michael Gibson discuss: Demographic Disparities in Tafamidis Treatment and Clinical Outcomes Across the United States
Disclosures: Supported by an independent educational grant from BridgeBio Pharma Inc.
Dr. Fatima Rodriguez and Dr. C. Michael Gibson discuss: A Proposed Stepwise Approach to Evaluation, Treatment and Tracking of Coronary Atherosclerosis
Sponsored by Cleerly, Women as One and International Atherosclerosis Society
Dr. Sandesh Dev and Dr. C. Michael Gibson discuss: Geographic Disparities in Transthyretin Amyloid Cardiomyopathy Prevalence in United States Veterans.
Disclosures: Supported by an independent educational grant from BridgeBio Pharma Inc.
Dr. Jim Januzzi and Dr. C. Michael Gibson discuss: Acoramidis Lowers NT-proBNP in a Larger Proportion of ATTRibute-CM Study Participants With Transthyretin Amyloid.
Disclosures: Supported by an independent educational grant from BridgeBio Pharma Inc.
Dr. Kevin Alexander and Dr. C Michael Gibson discuss: Acoramidis Effect on All-Cause Mortality in Patients with p.V142I (V122I) Variant ATTR-CM: Findings From the ATTRibute-CM Study
Disclosures: Supported by an independent educational grant from BridgeBio Pharma Inc.